Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Necitumumab plus Gemcitabine-Cisplatin in Stage IV Squamous NSCLC
NCT01788566Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2013
- Primary completion
- Aug 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of necitumumab in squamous cell carcinoma of the lung (SCCL), sponsored by Eli Lilly and Company. Started Mar 2013; status: completed.
02
Drugs
necitumumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT01788566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01788566.